Autor(es): Amaral, Maria João ; Oliveira, Rui C. ; Donato, Paulo ; Tralhão, José Guilherme
Data: 2023
Identificador Persistente: https://hdl.handle.net/10316/112403
Origem: Estudo Geral - Universidade de Coimbra
Assunto(s): Pancreatic cancer; Biomarkers; Oncogenic mutations; Liquid biopsies; Humans; Liquid Biopsy; Mutation; Biomarkers, Tumor; Pancreatic Neoplasms
Pancreatic cancer is one of the most fatal malignancies, as approximately 80% of patients are at advanced stages by the time of diagnosis. The main reason for the poor overall survival is late diagnosis that is partially due to the lack of tools for early-stage detection. In addition, there are several challenges in evaluating response to treatment and predicting prognosis. In this article, we do a review of the most common pancreatic cancer biomarkers with emphasis in new and promising approaches. Liquid biopsies seem to have important clinical applications in early detection, screening, prognosis, and longitudinal monitoring of on-treatment patients. Together with biomarkers in imaging, can represent valuable alternative non-invasive tools in order to achieve a more effective management of pancreatic cancer patients.
Open access funding provided by FCT|FCCN (b-on).
